Skip to main content
Premium Trial:

Request an Annual Quote

John Mendlein

Editas Medicine has appointed John Mendlein to its board of directors. 

Mendlein is CEO of aTyr Pharma. He also serves on the boards of Fate Therapeutics (as vice chairman), Moderna Therapeutics, Pronutria Biosciences, and the emerging companies board of Biotechnology Industry Organization.

Prior to joining aTyr, he served as CEO of both Adnexus Therapeutics and Affinium Pharmaceuticals.

Mendlein holds a PhD in physiology and biophysics from the University of California, Los Angeles, a JD from the University of California, Hastings College of the Law and a BS in biology from the University of Miami.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.